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Abstract
Background: Little is known about the burden of common mental disorders in Russia despite high levels of suicide
and alcohol-related mortality. Here we investigated levels of symptoms, self-reports of ever having received a
diagnosis and treatment of anxiety and depression in two Russian cities.
Methods: The study population was men and women aged 35–69 years old participating in cross-sectional population-
based studies in the cities of Arkhangelsk and Novosibirsk (2015–18). Participants completed an interview which included the
PHQ-9 and GAD-7 scales, questions on whether participants had ever received a diagnosis of depression or anxiety, and
health service use in the past year. Participants also reported current medication use and medications were coded in line
with the WHO anatomical therapeutic classification (ATC). Depression was defined as PHQ-9≥ 10 and Anxiety as GAD-7≥
10.
Results: Age-standardised prevalence of PHQ-9≥ 10 was 10.7% in women and 5.4% in men (GAD-7≥ 10 6.2% in women;
3.0% in men). Among those with PHQ-9≥ 10 17% reported ever having been diagnosed with depression (equivalent
finding for anxiety 29%). Only 1.5% of those with PHQ-9≥ 10 reported using anti-depressants and 0.6% of those with GAD-
7≥ 10 reported using anxiolytics. No men with PHQ-9≥ 10 and/or GAD-7≥ 10 reported use of anti-depressants or
anxiolytics. Use of health services increased with increasing severity of both depression and anxiety.
Conclusion: There was a large gap between symptoms and reporting of past diagnosis and treatment of common mental
disorders in two Russian cities. Interventions aimed at improving mental health literacy and reducing stigma could be of
benefit in closing this substantial treatment gap.
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Background
Common mental disorders (depression and anxiety) are
important public health concerns worldwide [1, 2]. Rela-
tively little attention has been given to the burden of
common mental disorders and their treatment in Russia,
despite the country having high rates of suicide and
alcohol-related mortality [3–6]. Depressive symptoms
have been shown to predict cardiovascular and all-cause
mortality in the Russian population [7].
Three population-based studies from the start of the
millennium found a high prevalence of symptoms of de-
pression [8–10] and anxiety [9]. The HAPIEE study
which assessed depression using the Centre for Epidemi-
ologic studies depression scale (CES-D) > 16 among men
and women aged 45–64 in the city of Novosibirsk
(1999–2000) found a prevalence of 23% in men and 44%
in women [8]. The Arkhangelsk Study (2000) assessed
depression and anxiety using binary questions about
feeling depressed in the past 2 weeks/anxious in the past
year found prevalence of depression 10% in men and
34% in women and of anxiety 25% in men and 53.2% in
women [9]. A study of 885 adults aged 18–64 living in
rural Udmurtia in 1995 found 27.3% participants met
ICD-10 criteria for a mood disorder in the past month
when interviewed using the Composite International
Diagnostic Interview [10]. In the past 20 years, Russia
has undergone substantial political, economic and social
change [11]. It is therefore timely to investigate the bur-
den of common mental disorders and associated levels
of treatment in present day Russia. Early findings from
the more recent ESSE-RF multi-centre study (2013–14)
suggests the burden remains high with a 25.6% preva-
lence of depression and 46.3% prevalence of anxiety
among 16,877 men and women aged 25–64 years old
assessed using the Hospital Anxiety and Depression
Scale (HADS) score ≥ 8 [12]. None of these studies in-
vestigated issues to do with levels of diagnosis or treat-
ment within the general population. However a study of
155 primary care users from St Petersburg in Russia has
found low levels of treatment for depression among 55
participants identified as having symptoms using CES-D,
particularly with pharmacotherapy with no participants
with depression using antidepressants [13].
Treatment for mental health problems in Russia pri-
marily takes place within specialist services with a focus
on treatment delivery through psychiatric outpatient dis-
pensaries and hospitals [14–17]. Seeking treatment pri-
vately is also an option for those who can afford it.
Assessment and treatment within primary care is rare
[15, 16, 18, 19]. However if those with depression and
anxiety are more likely to attend general health care ser-
vices this may equate with missed opportunities for care.
One potential reason for low levels of diagnosis and
treatment is lack of contact with health services in
general however in several populations, including the
primary care users in the study from St Petersburg [20],
common mental disorders have been found to be associ-
ated with higher use of general health services [20–22].
In this study we investigated the prevalence of symp-
toms depression and anxiety, self-reports of ever being
diagnosed with depression and anxiety, and one specific
aspect of treatment (use of anti-depressants and anxio-
lytic medication) in the general population in two Rus-
sian cities. We also investigated the associations between
severity of symptoms and health service use. Since phys-
ical co-morbidities may drive an association between
mental health symptoms and health care use findings




The study population was men and women aged 35–69
years participating in the Know Your Heart study
(2015–18). This was a cross-sectional population-based
survey set up to investigate reasons for high cardiovascu-
lar disease mortality in Russia that collected a wide-
range of information about participants’ physical and
mental health and health service use and medications.
Detailed methodology of the study including response
rates have been described previously [23].
Recruitment took place in two Russian cities –
Arkhangelsk, in the North of European Russia and
Novosibirsk in Western Siberia. Novosibirsk is the third
largest city in Russia, after Moscow and St Petersburg,
with a population of 1,500,000 while Arkhangelsk is a
smaller city with a population of approximately 350,000
people. Data from the Russian census 2010 shows that
the age distribution of the two cities was similar to the
National average but the proportion of people with
higher education was higher in Novosibirsk compared to
the Urban Russian population as a whole while in
Arkhangelsk it was similar. Consistent with patterns for
all-cause mortality and cardiovascular disease mortality
at the time of study Russian state statistics showed
higher mortality from both suicide and alcohol-related
poisoning in Arkhangelsk than Novosibirsk.
Addresses of eligible participants were identified from
Territorial Health Insurance Fund records with sampling
stratified by age, sex and district (four districts per city).
Trained interviewers visited randomly selected addresses
and invited participants of the correct expected age and
sex to take part in the study. Excluding addresses which
were invalid or where no one of the correct age or sex
was resident response rates were 53.1% in Arkhangelsk
and 26.5% in Novosibirsk. The target population of the
study was men and women aged 35–69.
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If participants agreed to take part the interviewer car-
ried out a face to face interview, in the majority of cases
in the participants’ home, which included the questions
of the PHQ-9, GAD-7, whether participants had ever re-
ceived a diagnosis of depression or anxiety, self-reported
diseases, socio-demographic factors and health behav-
iours (smoking and alcohol use). After this interview
participants were invited to attend a health check exam-
ination at a polyclinic which 89% of participants
attended. Data on medication use were collected at the
health check.
Measurement of symptoms, ever having received a
diagnosis and treatment of depression and anxiety
Depression was measured using the PHQ-9 [24]. This is a
nine-item scale with questions on symptoms of depression
in the past 2 weeks. Each question has four response op-
tions (not at all/several days/more than half of the days/
nearly every day). A severity score was calculated by sum-
ming responses to each question with “not at all” re-
sponses scored as zero and “nearly every day” as three. A
cut point of ≥10 or above was used to define moderate de-
pression as a binary outcome and the following cut points
to define depression severity: 5–9 mild depression, 10–14
moderate depression, 15–19 major depression and ≥ 20
major severe depression [24]. Anxiety was measured using
the GAD-7 a 7-item scale with questions on symptoms of
anxiety in the past 2 weeks [25]. Scoring and calculation of
the severity score was the same as for the PHQ-9. A cut
point of ≥10 or above was used to define moderate anxiety
as a binary outcome and the following cut points to define
anxiety severity: 5–9 mild anxiety, 10–14 moderate anx-
iety and ≥ 15 severe anxiety [25]. Standard Russian transla-
tions of the PHQ-9 and GAD-7 were used (www.
phqscreeners.com).
Ever having received a diagnosis of depression or anx-
iety was assessed through self-report using these two
questions: “Have you ever been told by a doctor (been
diagnosed) that you have depression?” and “Have you
ever been told by a doctor (been diagnosed) that you
have anxiety?” with response categories yes/no.
Participants were asked to bring all their medications
to the health check where medically trained interviewers
asked about current medication use and recorded the
name, dose, indication and frequency of use (up to 7
medications). If participants did not bring medications
with them (73% of participants did not bring medica-
tions) they were asked verbally to report this informa-
tion. Medications were coded using the International
WHO Anatomical Therapeutic Chemical (ATC) classifi-
cation system (https://www.whocc.no/). Use of anti-
depressant medication was defined as any medication in
class N06A and anxiolytic medication as any medication
in class N05B. Use of drugs containing hypnotic or
sleeping medications defined as any medication in class
N05C were also considered.
Health service use
Use of health services was measured by considering the
number of visits to a doctor and the number of hospital
admissions. Participants were asked how many times in
the past 12 months they had visited the following types
of physician: district physician/polyclinic cardiologist/
other polyclinic specialist/hospital cardiologist/other
hospital doctor. For each type of doctor visited the re-
sponse options were integers 0 to 5+. The visits to each
type of doctor were summed together treating “5+” as 5
allowing for a maximum possible number of 25 visits to
a doctor. Number of hospital admissions was measured
from the question “In the last 12 months, how many
times have you been hospitalised (stayed in hospital
overnight)?” The number of times was an open response
(no categories given).
The number of medications used per participant
among the sub-set of participants with data on medica-
tion use was also considered as a further indicator of
medical care.
Self-reported physical morbidity
Analyses on associations with health service and medica-
tion use were stratified by report of physical co-
morbidities in the baseline interview “Have you ever
been told by a doctor (been diagnosed) that you have:
cancer, angina, stroke, rheumatoid arthritis, osteoarth-
ritis, asthma, diabetes, chronic lung disease, myocardial
infarction, kidney disease, heart failure?” This was to in-
vestigate to what extent associations may be due to
poorer physical health leading to both worse mental
health and increased use of health care.
Other variables of interest
Potential confounders of the association between common
mental disorders and health service use considered were
demographic factors (age, sex and marital status), socio-
economic factors (education (classified into three groups
lower, middle and higher) self-perceived financial status
measured on a 6 item likert scale and employment status
(in regular paid employment or not)) and health behav-
iours (smoking status (current smoker, ex-smoker, never
smoker), alcohol use measured in terms of volume of
ethanol from beer, wine, and spirits in the past year and
CAGE score [26] for problem drinking adapted to a 12
month reference period. While current socio-economic
circumstances and health behaviours are also potentially
mediators of the relationship between mental health and
health service use our aim here was to investigate whether
common mental disorders were associated with increased
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help seeking from medical services which may be con-
founded by worse physical health.
Statistical analysis
Prevalences of symptoms indicating moderate depres-
sion and anxiety, ever having received a diagnosis and
treatment in the general population sample were calcu-
lated stratified by sex and city and directly standardised
by age to the European 2013 Standard Population for
those aged 35–69. Between city differences in prevalence
of symptoms were investigated by fitting logistic regres-
sion models with moderate depression as the outcome,
city as the main exposure and adjustments for a) age
and sex b) model 1 plus socio-economic factors (educa-
tion, financial status, employment status) and c) model 2
plus health behaviours (smoking, alcohol use).
Distribution of use of health service variables were
skewed therefore median (IQR) number of visits to a
doctor, hospital admissions and use of medications were
considered by category of depression and anxiety sever-
ity and modelled using negative binomial regression as
an alternative to poisson regression due to over-
dispersion of the outcome variables. Due to small num-
ber of participants with severe major depression (n = 27)
the two major depression categories were collapsed for
these analyses. Models were fitted stratified by reporting
of physical co-morbidities. Negative binomial regression
models were fitted for each outcome and mental health
exposure separately adjusting a) for age sex and city and
b) adjusting for age, sex, city, marital status, socio-
economic factors and health behaviours.
Statistical analyses were done in Stata 15 [27].
Results
The sample size was 5077 participants aged 35–69 years
at the time of the baseline interview (42.8% male, mean
age 54 (SD 9.8)). Of these participant 4060 attended the
health check and had data available on use of
medications.
Prevalence of symptoms, ever having received a
diagnosis and treatment of depression and anxiety
The age-standardised prevalence of moderate depression
(PHQ-9 ≥ 10) for those aged 35–69 in Novosibirsk was
10.6% (95% CI 9.4, 11.9%) and in Arkhangelsk 6.3% (95%
CI 5.4, 7.3%). The age-standardised prevalence of moder-
ate anxiety (GAD-7 ≥ 10) was 6.0% (95% CI 5.1, 7.0%) in
Novosibirsk and 3.8% (95% CI 3.0, 4.6%) in Arkhangelsk.
The odds of moderate depression were higher in Novo-
sibirsk after adjusting for age and sex (OR 1.76 95% CI
1.43, 2.16). The difference between sites was attenuated
but not fully explained by adjustment for socio-economic
factors (OR 1.53 95% CI 1.24, 1.89). Additional adjustment
for differences in health behaviours between the study
populations in each city did not explain this further (1.53
95% CI 1.27, 1.93). Distribution of socio-demographic fac-
tors and health behaviours between the study populations
of the two cities are shown in Supplementary Table 1.
The distribution of severity scores on the PHQ-9 and
GAD-7, prevalence of scores≥10 and reports of ever hav-
ing been diagnosed with depression and anxiety by sex
and city are shown in Table 1. There were consistently
higher prevalences in Novosibirsk compared to Arkhan-
gelsk but the pattern of results was the same in both cit-
ies: prevalence of moderate depression (PHQ-9 ≥ 10) and
anxiety (GAD-7 ≥ 10) was appreciably higher in women
than in men. The prevalence of reporting ever having re-
ceived a diagnosis of depression was substantially lower
than point prevalence of moderate depression based on
symptoms. This was a consistent finding in men and
women. Levels of reporting of ever having received a
diagnosis of anxiety were slightly higher than point
prevalence in women and similar to point prevalence in
men.
Use of anti-depressants and anxiolytic medications in
the general population was extremely low in both cities
(10 participants reported use of anti-depressants and 8
reported use of anxiolytics data from both cities com-
bined). Use of sleeping medications in the general popu-
lation (n = 27 0.7%) was slightly more common than
either anti-depressants (0.3%) or anxiolytics (0.2%) but
also very low. The prevalence of use of medications
among those with PHQ-9 ≥ 10 and GAD-7 ≥ 10 is shown
in Table 2. Levels of treatment of depression and anxiety
with anti-depressant and anxiolytic medication was ex-
tremely low and no men with symptoms of either condi-
tion were receiving any pharmacological treatment.
The overlap between PHQ-9 ≥ 10 and GAD-7 ≥ 10 and
report of ever having received a diagnosis of depression
is shown in Fig. 1a. The equivalent for reporting ever
having received a diagnosis of anxiety is shown in Fig.
1b. Despite differences in absolute prevalences the find-
ings for men and women were similar and the results
are shown for men and women combined. The preva-
lence of co-morbidity was very high – particularly for
those with GAD-7 ≥ 10 of whom 69.1% also had PHQ-
9 ≥ 10 while 37.4% of those with PHQ-9 ≥ 10 also had
GAD-7 ≥ 10. Among participants with PHQ-9 ≥ 10 the
proportion who reported they had ever received a diag-
nosis of depression was low (16.9%). Prevalence of
reporting ever receiving a diagnosis of anxiety among
participants with GAD-7 ≥ 10 was slightly higher
(28.8%).
Associations with use of health services and medications
The age and sex adjusted associations between severity
of depression and anxiety with use of health services and
medications among those with no self-reported physical
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co-morbidities are shown in Table 3. There were
strong associations between both severity of depres-
sion and anxiety and the health service use outcomes:
visits to a doctor and admissions to hospital and also
some evidence for a trend with number of medica-
tions used with rates increasing with severity of the
mental health conditions. Findings remained with only
slight attenuation of rate ratios on adjustment for
socio-demographic factors and health behaviours
(Table 3). The strong association between severity of
depression and anxiety and the measures of health
service use was also seen in the sub-group of
Table 1 Severity of depression and anxiety and age-adjusted prevalence of moderate depression and anxiety (symptoms and report
of ever having received a diagnosis) by city and sex













N (%) N (%) N (%) N (%) N (%) N (%)
PHQ-9 severity score
No symptom (< 5) 784 (76.7) 902 (63.1) 807 (70.1) 827 (56.1) 1591 (73.2) 1729 (59.5)
Mild depression (5–9) 198 (19.4) 407 (28.5) 259 (22.5) 444 (30.1) 457 (21.0) 851 (29.3)
Moderate depression (10–14) 29 (2.8) 87 (6.1) 56 (4.9) 138 (9.4) 85 (3.9) 225 (7.8)
Major depression (15–19) 9 (0.9) 27 (1.9) 24 (2.1) 52 (3.5) 33 (1.5) 79 (2.7)
Major depression- severe (≥ 20) 2 (0.2) 7 (0.5) 5 (0.4) 13 (0.9) 7 (0.3) 20 (0.7)
Age-standardised prevalence of moderate depression













Age-standardised prevalence ever diagnosed with














No symptoms (< 5) 888 (86.9) 1070 (74.8) 957 (83.2) 1053 (71.4) 1845 (84.9) 2123 (73.1)
Mild anxiety (5–9) 112 (11.0) 292 (20.4) 150 (13.0) 312 (21.2) 262 (12.1) 604 (20.8)
Moderate anxiety (10–14) 14 (1.4) 46 (3.2) 34 (3.0) 73 (5.0) 48 (2.2) 119 (4.1)
Severe anxiety (≥ 15) 8 (0.8) 22 (1.5) 10 (0.9) 36 (2.4) 18 (0.8) 58 (2.0)
Age-standardised prevalence of moderate anxiety













Age-standardised prevalence ever diagnosed













a 11 participants responded “difficult to answer”. They were coded as missing
b12 participants responded “difficult to answer”. They were coded as missing
Table 2 Use of antidepressants, anxiolytics and sleeping medications among those with PHQ-9 ≥ 10 and GAD-7 ≥ 10
N with medication data Use of anti-depressants (N06A) Use of anxiolytics (N05B) Use of sleeping medication (N05C)
Moderate depression (PHQ-9≥ 10)
Total 334 1.5% 0.6% 1.5%
Men 86 0.0% 0.0% 0.0%
Women 248 2.0% 0.8% 2.0%
Moderate anxiety (GAD-7≥ 10)
Total 181 2.2% 0.6% 2.8%
Men 46 0.0% 0.0% 0.0%
Women 138 2.9% 0.7% 3.7%
Co-morbid moderate depression and anxiety (PHQ-9 & GAD-7≥ 10)
Total 121 3.3% 0.8% 3.3%
Men 26 0.0% 0.0% 0.0%
Women 95 4.2% 1.1% 4.2%
Cook et al. BMC Psychiatry          (2020) 20:537 Page 5 of 11
participants who reported one or more physical co-
morbidity (Supplementary Table 2).
Discussion
In this cross-sectional survey of the general population
in the Russian cities of Arkhangelsk and Novosibirsk the
age-adjusted point prevalence of moderate depression
(PHQ-9 ≥ 10) and anxiety (GAD-7 ≥ 10) varied between
the two cities with a higher prevalence of both in Novo-
sibirsk (moderate depression 10.6%; moderate anxiety
6.0%) than Arkhangelsk (moderate depression 6.3%;
moderate anxiety 3.8%). In both cities the prevalence of
common mental disorders varied by gender with higher
prevalence in women. Reporting of ever having received
a diagnosis of depression was 3 times lower than point
prevalence for depression in men and 2 times lower in
women. Use of anti-depressants and anxiolytic medica-
tions was extremely low with no men with symptoms of
depression or anxiety receiving any pharmacological
treatment (anti-depressants or anxiolytics), despite a
higher use of health services and other medications
among those with symptoms of depression and anxiety.
Separate studies of the prevalence of depression and
anxiety have been carried out some years ago in both
Arkhangelsk (the Arkhangelsk study 2000) and Novosi-
birsk (HAPIEE 1999–2000) which found substantially
higher prevalences of both depression and anxiety.
Russia has experienced rapid social and political change
over time therefore it is feasible prevalence of common
mental disorders may have changed in the time frame
between these studies, however it is difficult to make
formal comparisons between the three studies given dif-
ferences in methodology for deriving case definitions.
The more recent ESSE-RF survey from 2012 to 13 which
included 10 regions in Russia used the HADS to assess
depression symptoms also found higher prevalences of
depression (25.6%) and anxiety (46.3%) closer to the
earlier studies [12]. It is impossible to know from our
data whether this indicates true variation or large differ-
ences based on assessment methods and/or recruitment
of participants.
The prevalence of depression we have found is com-
parable to more recent population-based surveys in
other countries which have used PHQ-9 to assess de-
pression with estimates of moderate depression (PHQ-
9 ≥ 10) from Germany [28], Hong Kong [29], Korea [30],
Sweden [31] and the USA [30] ranging from 4.2% (Hong
Kong) to 10.8% (Sweden). A population study using
GAD-7 ≥ 10 from Germany [32] found a prevalence of
anxiety of 5.9% similar to the prevalences found here,
while studies from Malaysia [33] and Sweden [31] using
a lower cut point of ≥8 found prevalences of 8.2 and
14.7% respectively (corresponding age-standardised
prevalences≥8 here were 9.0% Novosibirsk and 6.0%
Arkhangelsk). It should be noted that other population-
based studies using GAD-7 and PHQ-9 included a wider
a
b
Fig. 1 a Overlap in symptoms of depression, anxiety and report of ever receiving a diagnosis of depression. b Overlap in symptoms of anxiety,
depression and report of ever receiving a diagnosis of anxiety
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age range of participants than were included here which
limits comparability with our study findings. Also we
found in this study that there were differences between
the two cities which were not explained by socio-
economic circumstances or health behaviours of the in-
cluded study participants. While in our study the preva-
lence of both depression and anxiety was higher in
Novosibirsk than Arkhangelsk, in contrast to Russian
state statistics which show rates of mortality from sui-
cide are higher in Arkhangelsk. This may be an indicator
that the study is affected by selection bias. However if
these findings represent true differences they suggest
there are other between city level factors besides levels
of reported symptoms which explain the higher suicide
rates in Arkhangelsk, for example differences in alcohol
use. Mortality from accidental poisoning by alcohol from
Russian State statistics is also substantially higher in
Arkhangelsk than Novosibirsk indicating a higher preva-
lence of hazardous drinking.
The levels of ever receiving a diagnosis and treat-
ment for depression and anxiety in our study popula-
tion were very low. Striking findings were both lower
prevalence of reported lifetime diagnosis compared to
point prevalence and the extremely low levels of use
of anti-depressant and anxiolytic medications. Only
10 participants in the entire sample reported use of
anti-depressants and 8 anxiolytics. No men with
PHQ-9 ≥ 10 received any pharmacological treatment.
This is consistent with a study of 155 primary care
users in St Petersburg where none of the 55 partici-
pants identified as having symptoms of depression
were receiving pharmacological treatment [13]. In
contrast the other populations included in the same
study medication use ranged from 4% in Be’er Sheva
to 38% in Seattle [13]. Our finding are also in con-
trast to larger population-based studies in other pop-
ulations such as the NHANES survey from the USA
(2005–8) where among the general population 27.0%
of those with moderate depression (PHQ-9 10–14)
and 31.8% with major depression (≥15) received
pharmacological treatment [34] and the 2014 Adult
Psychiatric Morbidity Survey for England where 55%
of those with depression according to the Clinical
Interview Schedule - Revised (CIS-R) had received
medication [35]. Findings are particularly striking
given that anxiolytics (although not anti-depressants)
are available without prescription in Russia therefore
access is easier than in many other settings. However
it is possible participants did not report medications
used for these purpose either due to associated stigma
or because they did not consider drugs obtained over
the counter for self-management of mood counted as
“medications” in the traditional sense. Here we con-
sidered only medications within the ATC classes and
have not looked at self-medication with alternative
medicinal treatments marketed for similar purposes.
Our findings in relation to ever having received a diag-
nosis are also substantially lower than the English study
where 70% of participants with symptoms of depression
had also received a diagnosis of depression at some stage
in their life [35]. No data were available on use of non-
pharmacological treatments (such as psychotherapy) in
the current study. However given the low levels of par-
ticipants reporting ever having received a diagnosis of
depression or anxiety (in particular depression) it seems
unlikely that the use of talking therapies over pharmaco-
logical management is the primary reason for the very
low levels of pharmacological treatment found in this
population. It seems more likely that we have identified
here a very large gap in diagnosis and treatment of com-
mon mental disorders. This cannot be explained in
terms of lack of contact with health services per se as
even after restricting to those who did not report co-
morbid physical illnesses and adjusting for socio-
demographic and behavioural risk factors those report-
ing symptoms of depression and anxiety had more con-
tact with health services and were taking more
medications than those who did not. There was also a
clear dose response with severity of symptoms. This is
consistent with findings in other settings that use of
(non-mental) health services is higher among those with
mental health symptoms [20–22]. We have identified
here missed opportunities for diagnosis and providing
appropriate treatment for those with common mental
health disorders. This may be influenced both by beliefs
of doctors, but also by the attribution and presentation
of symptoms by patients seeking help [36]. Low avail-
ability and perceived value of including mental health
treatment within primary care may also be an important
factor in explaining the treatment gap as currently the
main options to receive treatment for mental health
problems are through specialist services or private treat-
ment, which is not affordable for the majority. In the
study of primary care users in St Petersburg cost of
treatment was raised by participants as a major barrier
to treatment [37].
Our findings of low levels of treatment and diagnosis
are consistent with previous studies on attitudes and be-
liefs about depression where presented with vignettes
describing people with symptoms of depression Russian
participants compared to participants from Germany
[38] and the United States [39] were less likely to attri-
bute depression to biological rather than psycho-social
causes [38, 39], more likely to indicate depression was
related to “weak will” [38, 39] and less likely to endorse
help seeking for the individual [39], while in a similar
comparative study Russian participants were less likely
to endorse seeking help from medical sources than
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British participants and scored lower on a scales indicat-
ing tolerance towards descriptions of people with mental
health problems [40]. Interventions aimed at improving
mental health literacy [41–43] and reducing stigma [44,
45] both in the general population and among health
care professionals could be of benefit in closing the
treatment gap.
This study has several limitations to consider in inter-
pretation of the findings:
Firstly all data on common mental disorders, including
history of diagnosis and treatment, and health service
use are self-reported. We were able to look at prevalence
of depression and anxiety symptoms at one point in time
based on symptoms in the past 2 weeks but this cannot
be considered equivalent to clinical diagnosis and does
not reflect longer term duration of symptoms. Although
the PHQ-9 and GAD-7 are validated instruments they
have not been validated for use in Russia. Interviews in
this study were conducted face to face and it is possible
that some participants may not have reported having re-
ceived a diagnosis of depression or anxiety or disclosed
medication use at the health check due to concerns
about associated stigma. Furthermore the proportion of
participants who brought their medications to the health
check examination was small (27%). For the majority
reporting was verbal only and some level of measure-
ment error due to errors in reporting by participants
who may not remember or be aware of the names of all
their medication is also feasible. The low use of medica-
tions is however consistent with the very low reporting
of diagnosis also found in this study.
Secondly this was a cross-sectional study and we are
not able to determine the temporal direction of associ-
ation between common mental disorder and health ser-
vice use, particularly given the time frame for asking
about symptoms of depression was the past 2 weeks and
visits to doctors and hospital admissions the past 12
months. However given symptoms of common mental
disorders are fairly persistent it is likely this does reflect
pattern of symptoms in the past 12 months. Although
analyses were restricted to those who did not report co-
morbid physical health problems this was not an ex-
haustive list and there is still potential confounding due
to co-morbidities not included or not reported by partic-
ipants or undiagnosed at the time of the interview. How-
ever our findings were robust to stratification by the
stated co-morbidities and controlling for a range of po-
tential confounders.
Thirdly response rates for one city (Novosibirsk)
were particularly low which may have affected the
representativeness of the sample. Response rates for
Arkhangelsk were higher but not 100% and it is pos-
sible that selection into the study may have been dif-
ferential by mental health status. The impact of bias
is difficult to estimate. Comparisons of the educa-
tional profile of the study participants with the 2010
census [23] showed ratio of the observed to expected
was 0.98 (95% CI 0.92, 1.04) for Arkhangelsk but with
variation over age with higher than expected educa-
tion at younger ages and lower than expected educa-
tion in the older participants. For Novosibirsk there
was some evidence that educational profile of partici-
pants was higher than expected (1.14 (95% CI 1.07,
1.21)) but this was consistent across age groups.
Those with more severe depression at baseline were
less likely to attend the subsequent health check [23].
If the same were true for initial participation we may
have under-estimated the prevalence of common
mental disorders in this population. Within the two
cities selection was within four districts. These were
selected to represent a range of socio-demographic
and mortality levels in each city but recruitment was
not from all city districts so may not be generalisable
to the whole city. To this extent prevalence estimates
should be interpreted with caution however the lack
of treatment in those identified here with moderate
depression is valid and an important finding.
Finally our findings are not generalisable to the whole
of Russia. Within the two cities included there was vari-
ation in point prevalence of depression and anxiety
symptoms although the finding of strikingly low use of
anti-depressants was consistent in both.
Conclusions
In conclusion here we have identified a substantial gap
in diagnosis and treatment of common mental disorders
among the general population in two Russian cities. Fur-
ther work understanding the barriers to diagnosis and
appropriate treatment in Russia is needed in order to de-
sign appropriate interventions to improve provision of
care for common mental disorders in this population.
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